(Q37924427)

25 August 2017

1 reference

title

Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer (English)

1 reference

25 August 2017

Stefan Glück

1

1 reference

25 August 2017

Fariborz Gorouhi

series ordinal

2

1 reference

25 August 2017

publication date

1 September 2011

1 reference

American Journal of Health-System Pharmacy

25 August 2017

published in

1 reference

25 August 2017

volume

68

1 reference

25 August 2017

issue

18

1 reference

25 August 2017

page(s)

1699-1706

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

The prevention and management of distant metastases in women with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

The importance of distant metastases in hormone-sensitive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Hormonal therapies for early breast cancer: systematic review and economic evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100492

31 March 2020

Identifiers

DOI

10.2146/AJHP100492

1 reference

25 August 2017

1 reference